Wendy Guy - 26 Jul 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
28 Jul 2026, 20:22:26 UTC
Prior SEC filing
01 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact

Key filing fact

Wendy Guy filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 28 Jul 2026.

Key facts

  • This page summarizes Wendy Guy's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
  • 1 reported transaction and 2 derivative rows are listed below.
  • Accepted by SEC: 28 Jul 2026, 20:22.

Change

  • Previous filing in this sequence was filed on 01 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001799360 Primary reporting owner

Guy Wendy

Relationship
Chief Administrative Officer
Address
C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature
/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact
Signature date
28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCSA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
14,394
Date
26 Jul 2026
Ownership
Direct
PCSA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
333
Date
26 Jul 2026
Ownership
By CorLyst, LLC

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares
+9,450
Change %
+426%
Price
$0.000000*
Shares after
11,669
Date
26 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,450
Exercise price
$0.000000
Footnotes
F1, F3
PCSA holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
6,000
Date
26 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,000
Exercise price
$4.96
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

Footnote F2

Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

Footnote F3

Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .